Benoxaprofen improves psoriasis. A double-blind study

Kragballe, Knud

doi:10.1001/archderm.119.7.548

Cited by 44 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was demonstrated that LTB4 as well as peptido leukotrienes are involved in the stimulation of kératinocyte proliferation [18]. Increased amounts of 5-lipoxygenase products were also found in scales and exudates of lesional skin in chronic plaque psoriasis [6,7], Contrary to the effect of the cyclooxygenase inhibitor indometacin which exacerbates psoriatic le sions, Kragballe and Herlin [19] reported that benoxaprofen was of benefit in the treatment of psoriasis vulgaris. This clinical experience is based on a double-blind placebo-controlled study.…”

Section: Discussionmentioning

confidence: 99%

Effects of the Phthalazinone Azelastine on Epidermal Metabolism after Mechanical Skin Irritation

Kietzmann

Lubach²,

Mollière³

et al. 1992

Pharmacology

View full text Add to dashboard Cite

In female NMRI mice, the phthalazinone azelastine was administered orally once daily over 7 days. The drug influenced the epidermal thymidine triphosphate and amino acid incorporation rates at doses between 1 and 5 mg/kg. In control mice, an epidermal hyperproliferation induced by abrasion of superficial epidermal layers was characterized by enhanced prostaglandin and leukotriene concentrations in epidermal homogenate, an increase in thymidine triphosphate and amino acid incorporation and an increase in epidermal thickness. In mice treated with 1 mg/kg azelastine HC1, this epidermal reaction was changed. Compared to controls, the increase in leukotriene concentration was diminished, and that of prostaglandins was enhanced. The incorporation of thymidine triphosphate and of amino acids as well as the epidermal thickness and the ratio cell count/epidermal thickness were increased in irritated skin of azelastine-treated mice. In conclusion, azelastine influences the epidermal metabolism in irritated and unirritated skin. Therefore, a beneficial role of this phthalazinone in the treatment of psoriasis and related skin disorders seems to be possible.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of the Phthalazinone Azelastine on Epidermal Metabolism after Mechanical Skin Irritation

Kietzmann

Lubach²,

Mollière³

et al. 1992

Pharmacology

View full text Add to dashboard Cite

show abstract

“…5 Studies on leukotriene inhibitors for treating psoriasis have shown conflicting results, but most workers believe the efficacy of leukotriene inhibitors in the treatment of psoriasis. [6][7][8][9][10] Much literature has been generated on the possible role of cyclic nucleotides in psoriasis. It now appears that the mediator system, cyclic adenosine monophosphate (cAMP)-cyclic guanosine monophosphate (cGMP) as an off-on system, is not as simple as once perceived.…”

Section: Brief Review Of the Immunopathogenesis Of Psoriasis Relatingmentioning

confidence: 99%

“…Cannabinoids were shown to impair antigen processing in macrophages. 9 The macrophage/ T-cell cooperation is also supposed to be a target for cannabinoid action. 13 When administered in mice with subsequent animal challenge with aerosolized bacterial lipopolysaccharide (LPS), ∆ 9 -THC significantly decreased TNF-α level in mouse bronchoalveolar lavage.…”

Section: Cannabinoidsmentioning

confidence: 99%

Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition

Namazi

2005

Acad Dermatol Venereol

View full text Add to dashboard Cite

As the current antipsoriatic medications are commonly associated with deleterious side-effects, a determined search for safer agents, which could be used alone or in combination with current antipsoriatic drugs, would be very imperative. Psoriasis is believed to be characterized by a type 1 cytokine pattern; interferon-gamma, interleukin (IL)-2 and tumour necrosis factor (TNF)-alpha are predominantly expressed in this disorder. Nitric oxide, reactive oxygen species, histamine, leukotriene B4, and decreased [corrected] keratinocyte cyclic adenosine monophosphate/cyclic guanosine monophosphate (cAMP/cGMP) ratio are supposed to play roles in the pathogenesis of this disorder. Based on the immunopathogenesis of psoriasis, this paper introduces three novel, potential treatments for this clinical conundrum: (i) cannabinoids, which exert inhibitory effects on antigen processing and macrophage/T-cell interaction and also on the release of IL-2, TNF-alpha and nitric oxide from immune cells; (ii) loratadine, which is an antihistamine capable of increasing [corrected] the cAMP/cGMP ratio and the production of leukotriene B4; and (iii) allopurinol, which scavenges free radicals, inhibits the production of TNF-alpha, and downregulates the expression of intercellular adhesion molecule-1 and P2X7 receptors on monocytes/macrophages, which are involved in antigen presentation and production of the inflammatory response, respectively. Importantly, allopurinol, especially in combination with cyclosporin, has been shown to be effective against experimental autoimmune uveitis, which, like psoriasis, is a cell-mediated autoimmune disorder.

show abstract

“…For instance, benoxaprofen (2-[4-chlorophenyl]-c~-methyl-S-benzoxazole acetic acid), a nonsteroidal antiinflammatory drug and a weak inhibitor of both the lipoxygenase and cyclooxygenase pathways [Dawson et al, 19821, was reported by Kragballe and Herlin [1983], Allen and Littlewood [1982], and Kingston and Marks [1982] to improve the lesions of psoriasis. Furthermore, topical RS 43179 (a reported 5-lipoxygenase inhibitor) has been shown to be efficacious in double-blind trials in psoriasis [Lassus and Forsstrom, 19851.…”

Section: Antiinflammatory Agentsmentioning

confidence: 99%

Psoriasis: Hyperproliferative/inflammatory skin disorder

Ziboh

1988

Drug Development Research

View full text Add to dashboard Cite

The skin lesions in psoriasis are characterized by epidermal thickening (acanthosis), by a sustained inflammatory reaction that is evident in the dermis and epidermis, by altered epidermal differentiation (histologically characterized by para-and hyperkeratosis), and by the absence of granular layer. The development of future pharmacological agents for psoriasis, therefore, must recognize these various aspects of the disease activities. Chemical agents that are targeted toward only one aspect of the disease are unlikely to be totally beneficial. Although in its infancy, the possibility of therapeutic management via dietary manipulation by varying ratios of polyunsaturated fatty acids derived from vegetable and marine oils is promising. Furthermore, the possible beneficial effect of the dihydroxy metabolite of vitamin D3 ( 1~, 2 5 ( 0 H )~D~) , a naturally occurring substance, in the management of psoriasis is exciting and deserves to be fully explored. It is likely that this naturally occurring vitamin D3 metabolite may function to modulate keratinocyte differentiation.

show abstract

Benoxaprofen improves psoriasis. A double-blind study

Cited by 44 publications

References 0 publications

Effects of the Phthalazinone Azelastine on Epidermal Metabolism after Mechanical Skin Irritation

Effects of the Phthalazinone Azelastine on Epidermal Metabolism after Mechanical Skin Irritation

Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition

Psoriasis: Hyperproliferative/inflammatory skin disorder

Contact Info

Product

Resources

About